NarraFlect Insights
Before funding a biotech milestone, ask whether different results could change the next action. Two firsthand examples show how to keep that choice open without undervaluing the work.
Read the essay ↗Scientific rigor is not the same as decision usefulness.
Latest insights
The quality of the science is rarely the problem. More often, the problem is whether the evidence has been organized around the decision someone actually needs to make.
Read the insight ↗Every article is designed to clarify a real communication choice, not to repeat generic presentation advice.
Frameworks begin with cross-functional biotech work and the communication friction that appears between disciplines.
Examples are anonymized, confidential information is excluded, and illustrative situations are labeled.
Each piece should leave the reader with a sharper question, a usable distinction, or a practical next step.